Skrabek RQ, Galimova L, Ethans K, Perry D (2008). “Nabilone for the treatment of pain in fibromyalgia”. J Pain9 (2): 164–73. doi:10.1016/j.jpain.2007.09.002. PMID17974490.
Wissel J, et al. (2006). “Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial”. J Neurol.253 (10): 1337–41. doi:10.1007/s00415-006-0218-8. PMID16988792.
Cunningham D, et al. (1988). “A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues”. Eur J Cancer Clin Oncol24 (4): 685–9. doi:10.1016/0277-5379(88)90300-8. PMID2838294.
Niiranen A, Mattson K (1987). “Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy”. Am J Clin Oncol10 (4): 325–9. doi:10.1097/00000421-198708000-00014. PMID3039831.
Herman T, et al. (1979). “Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy”. N Engl J Med300 (23): 1295–7. doi:10.1056/NEJM197906073002302. PMID375088.
Frank B, et al. "Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study." British Medical Journal. 2008 Jan 8. [Epub ahead of print]. PMID18182416. doi:10.1136/bmj.39429.619653.80
Fraser, GA (2009). “The Use of a Synthetic Cannabinoid in the Management of Treatment-Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)”. CNS Neurosci Ther15 (1): 84–88. doi:10.1111/j.1755-5949.2008.00071.x. PMID19228182.
nih.gov
pubmed.ncbi.nlm.nih.gov
Skrabek RQ, Galimova L, Ethans K, Perry D (2008). “Nabilone for the treatment of pain in fibromyalgia”. J Pain9 (2): 164–73. doi:10.1016/j.jpain.2007.09.002. PMID17974490.
Wissel J, et al. (2006). “Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial”. J Neurol.253 (10): 1337–41. doi:10.1007/s00415-006-0218-8. PMID16988792.
Cunningham D, et al. (1988). “A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues”. Eur J Cancer Clin Oncol24 (4): 685–9. doi:10.1016/0277-5379(88)90300-8. PMID2838294.
Niiranen A, Mattson K (1987). “Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy”. Am J Clin Oncol10 (4): 325–9. doi:10.1097/00000421-198708000-00014. PMID3039831.
Herman T, et al. (1979). “Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy”. N Engl J Med300 (23): 1295–7. doi:10.1056/NEJM197906073002302. PMID375088.
Einhorn L, Nagy C, Furnas B, Williams S (1981). “Nabilone: an effective antiemetic in patients receiving cancer chemotherapy”. J Clin Pharmacol21 (8–9 Suppl): 64S–69S. PMID6271844.
Frank B, et al. "Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study." British Medical Journal. 2008 Jan 8. [Epub ahead of print]. PMID18182416. doi:10.1136/bmj.39429.619653.80
Fraser, GA (2009). “The Use of a Synthetic Cannabinoid in the Management of Treatment-Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)”. CNS Neurosci Ther15 (1): 84–88. doi:10.1111/j.1755-5949.2008.00071.x. PMID19228182.
